BioHarvest Sciences CEO Highlights Milestone Year in Shareholder Letter, Exceeds $36M Revenue, Expands Operations and Improves Balance Sheet

BioHarvest Sciences' CEO Ilan Sobel reflected on a milestone year in a shareholder letter, highlighting revenue growth, expanding operations, and balance sheet improvements. The company ended 2025 with an annualized revenue run rate exceeding $36 million and gross margins above 60%. The VINIA brand grew through product expansion and increased customer engagement, and the recent launch of VINIA Blood Flow Hydration Solution has been positively received. Sobel also noted that the company's CDMO business secured partnerships and validated the commercial relevance of its Botanical Synthesis platform.